WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018022438) COMBINATION THERAPY WITH MERESTINIB AND ANTI-PD-L1 OR ANTI-PD-1 INHIBITORS FOR USE IN THE TREATMENT OF CANCER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/022438    International Application No.:    PCT/US2017/043194
Publication Date: 01.02.2018 International Filing Date: 21.07.2017
IPC:
A61P 35/00 (2006.01), A61K 39/39 (2006.01), A61K 31/475 (2006.01)
Applicants: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center Indianapolis, Indiana 46285 (US)
Inventors: SCHAER, David Arlen; (US).
WALGREN, Richard A.; (US).
YAN, Sau-Chi Betty; (US)
Agent: DINGESS-HAMMOND, Elizabeth A.; (US).
BARRETT, Brian P.; (US)
Priority Data:
62/368,759 29.07.2016 US
Title (EN) COMBINATION THERAPY WITH MERESTINIB AND ANTI-PD-L1 OR ANTI-PD-1 INHIBITORS FOR USE IN THE TREATMENT OF CANCER
(FR) POLYTHÉRAPIE À BASE DE MÉRÉSTINIB ET D'INHIBITEURS ANTI-PD-L1 OU ANTI-PD-1 DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT DU CANCER
Abstract: front page image
(EN)The present invention relates to a combination therapy with N-(3-fluoro-4-(1-methyl- 6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide (merestinib, LY2801653), or a pharmaceutically acceptable salt thereof, and antibodies that bind human co-inhibitory immune checkpoints such as Programmed Death 1 Ligand 1 (PD-L1) or Programmed Death 1 (PD-1) for the treatment of various cancers.
(FR)La présente invention concerne une polythérapie à base de N-(3-fluoro-4-(1-méthyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phényl)-1-(4-fluorophényl)-6-méthyl-2-oxo-1,2-dihydropyridine-3-carboxamide (méréstinib, LY2801653), ou d'un sel de qualité pharmaceutique de ce dernier, et d'anticorps qui se lient à des points de contrôle immunitaire co-inhibiteurs humains tels que le ligand 1 de mort programmée 1 (PD-L1) ou la mort programmée 1 (PD-1) pour le traitement de divers cancers.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)